Literature DB >> 20418246

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.

Elisabetta Antonioli, Alessandra Carobbio, Lisa Pieri, Alessandro Pancrazzi, Paola Guglielmelli, Federica Delaini, Vanessa Ponziani, Niccolò Bartalucci, Lorenzo Tozzi, Alberto Bosi, Alessandro Rambaldi, Tiziano Barbui, Alessandro M Vannucchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20418246      PMCID： PMC2913097          DOI： 10.3324/haematol.2009.021444

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

Authors:  Francesco Passamonti; Elisa Rumi; Daniela Pietra; Matteo G Della Porta; Emanuela Boveri; Cristiana Pascutto; Laura Vanelli; Luca Arcaini; Sara Burcheri; Luca Malcovati; Mario Lazzarino; Mario Cazzola
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

2.  Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

Authors:  Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Rambaldi; Giovanni Barosi; Roberto Marchioli; Rosa Maria Marfisi; Guido Finazzi; Vittoria Guerini; Fabrizio Fabris; Maria Luigia Randi; Valerio De Stefano; Sabrina Caberlon; Agostino Tafuri; Marco Ruggeri; Giorgina Specchia; Vincenzo Liso; Edoardo Rossi; Enrico Pogliani; Luigi Gugliotta; Alberto Bosi; Tiziano Barbui
Journal:  Blood       Date:  2007-03-22       Impact factor: 22.113

3.  Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

Authors:  Giovanni Barosi; Gunnar Birgegard; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Jean-Jacques Kiladjian; Eva Lengfelder; Mary Frances McMullin; Francesco Passamonti; John T Reilly; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood       Date:  2009-03-10       Impact factor: 22.113

4.  Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

Authors:  Eric Lippert; François Girodon; Emma Hammond; Jaroslav Jelinek; N Scott Reading; Boris Fehse; Katy Hanlon; Mirjam Hermans; Céline Richard; Sabina Swierczek; Valérie Ugo; Serge Carillo; Véronique Harrivel; Christophe Marzac; Daniela Pietra; Marta Sobas; Morgane Mounier; Marina Migeon; Sian Ellard; Nicolaus Kröger; Richard Herrmann; Josef T Prchal; Radek C Skoda; Sylvie Hermouet
Journal:  Haematologica       Date:  2008-11-10       Impact factor: 9.941

5.  The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.

Authors:  Alexandre Theocharides; Jakob R Passweg; Michael Medinger; Renate Looser; Sai Li; Hui Hao-Shen; Andreas S Buser; Alois Gratwohl; André Tichelli; Radek C Skoda
Journal:  Haematologica       Date:  2008-09-11       Impact factor: 9.941

6.  Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.

Authors:  Anne Ricksten; Lars Palmqvist; Peter Johansson; Björn Andreasson
Journal:  Haematologica       Date:  2008-06-02       Impact factor: 9.941

7.  Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines.

Authors:  Oliver Bock; Julia Höftmann; Katharina Theophile; Kais Hussein; Birgitt Wiese; Jerome Schlué; Hans Kreipe
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

8.  JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Authors:  Kais Hussein; Oliver Bock; Katharina Theophile; Nils von Neuhoff; Thomas Buhr; Jerome Schlué; Guntram Büsche; Hans Kreipe
Journal:  Exp Hematol       Date:  2009-07-17       Impact factor: 3.084

9.  Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.

Authors:  François Girodon; Céline Schaeffer; Cédric Cleyrat; Morgane Mounier; Ingrid Lafont; Frédéric Dos Santos; Aurélie Duval; Aurélie Vidal; Marc Maynadié; Sylvie Hermouet
Journal:  Haematologica       Date:  2008-08-25       Impact factor: 9.941

10.  JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

Authors:  Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro M Vannucchi; Chiara M Dellacasa; Silvia Salmoiraghi; Federica Delaini; Alessandro Rambaldi; Tiziano Barbui
Journal:  Exp Hematol       Date:  2009-06-24       Impact factor: 3.084
  10 in total
  19 in total

Review 1.  What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors:  Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

2.  A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms.

Authors:  Giulia Minnucci; Giulia Amicarelli; Silvia Salmoiraghi; Orietta Spinelli; Marie Lorena Guinea Montalvo; Ursula Giussani; Daniel Adlerstein; Alessandro Rambaldi
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

3.  Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden.

Authors:  Ilana Renault Zalcberg; Jackline Ayres-Silva; Alexandre Mello de Azevedo; Cristiana Solza; Adelmo Daumas; Martin Bonamino
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

4.  Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis.

Authors:  Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Nikolai Podoltsev; Robert T Williams; Raajit K Rampal; Martin S Tallman; Amer M Zeidan; Maximilian Stahl
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-05-28

5.  Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Authors:  Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Amy V Jones; Paul Christos; Nicholas C P Cross; Richard T Silver
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

6.  Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy.

Authors:  Yufeng Li; Jiabin Zhu; Banghe Ding
Journal:  Int J Clin Oncol       Date:  2012-08-17       Impact factor: 3.402

7.  Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.

Authors:  Shuichi Shirane; Marito Araki; Soji Morishita; Yoko Edahiro; Yoshitaka Sunami; Yumi Hironaka; Masaaki Noguchi; Michiaki Koike; Eriko Sato; Akimichi Ohsaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2014-12-19       Impact factor: 2.490

8.  RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.

Authors:  Edwin Chen; Jong Sook Ahn; David B Sykes; Lawrence J Breyfogle; Anna L Godfrey; Jyoti Nangalia; Amy Ko; Daniel J DeAngelo; Anthony R Green; Ann Mullally
Journal:  Cell Rep       Date:  2015-12-10       Impact factor: 9.423

Review 9.  Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches.

Authors:  Karl Haslam; Stephen E Langabeer
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

10.  IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia.

Authors:  Xiao Huang; Tingting Ma; Yongmei Zhu; Bo Jiao; Shanhe Yu; Kankan Wang; Jian-Qing Mi; Ruibao Ren
Journal:  Front Med       Date:  2021-07-31       Impact factor: 9.927
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.